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Subacute Thyroiditis Secondary to Moderna COVID-19 Vaccine: A Case Report of
a Rare Manifestation
Abstract
The SARS-CoV-2 led to a global pandemic, infecting millions of lives within only a short period of time.
The symptoms of the disease vary with a subset of the population developing debilitating sequelae.
Through the emergency use authorization (EUA), multiple vaccines have been released against the novel
virus in record time. Long term and rare sequelae from the vaccine are poorly understood. DeQuervain’s
subacute thyroiditis is a self-limiting and painful inflammation of the thyroid gland usually associated with
viral infections. We report a rare case of subacute thyroiditis in a healthy 46-year-old woman presenting
with a painful swelling in the neck after receiving the Moderna mRNA-1273 SARS-CoV-2 vaccine. We seek
to elucidate a better understanding of rare vaccine side effects by documenting one of the first reported
cases of subacute thyroiditis induced by the SARS-CoV-2 vaccine.
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Introduction
The SARS-CoV-2 virus has been deemed a global pandemic by the World Health Organization.
The virus began in Wuhan, China with the first case officially reported to the WHO on December
31, 2019. The global pandemic was declared on March 11, 2020, the first global pandemic since
the H1N1 influenza outbreak in 2009.1 As of May 2021, there have been an estimated 162 million
confirmed cases with 3.3 million deaths worldwide.2 The majority of COVID-19 cases manifest
with respiratory symptoms with increasing reports of gastrointestinal, neurological, cardiac, and
nephrological manifestations as well. The Food & Drug Administration has streamlined the
approval of multiple SARS-CoV-2 vaccines, namely from Pfizer and Moderna. On December 18,
2020, the FDA issued an EUA for the Moderna mRNA-1273 SARS-CoV-2 vaccine for individuals
18 years of age and older.3 The phase 3 randomized, observer-blinded, placebo-controlled trial
was conducted at 99 centers in the United States with 30,420 participants with median follow-up
duration of 63 days.4 The majority of local and systemic adverse events included injection site
pain, erythema, swelling, lymphadenopathy, fever, headache, fatigue, myalgia, arthralgia, nausea,
vomiting, and chills.4 One of the key limitations of the clinical trial was the short duration of safety
follow-up, limiting the ability to detect rare adverse events.4 We present a case of a patient who
developed subacute thyroiditis after receiving the mRNA-1273 SARS-CoV-2 vaccine.
Case Report
An immunocompetent 46-year-old woman presented with right-sided neck pain accompanied by
low-grade fevers for several days after vaccination. The patient is a healthcare worker with no
prior COVID-19 diagnosis. She received her first dose of the vaccine followed by mild neck pain,
fever and myalgias. She did not need treatment as these symptoms were self-resolving in 72 hours.
32 days later, she received her second dose followed by persistent neck pain. There was no reported
history of respiratory symptoms, anosmia, dysgeusia, or any gastrointestinal symptoms. Her past
medical history includes chronic migraines for which she takes over-the-counter medication. She
has no history of an allergic reaction to previous vaccinations. Family history is notable for her
mother who underwent a thyroidectomy for unknown cause. On examination, the patient was
afebrile (98.8oF) with pulse rate of 119 beats per minute. Her blood pressure was 147/76 mm Hg,
respiratory rate 18 per minute, and oxygen saturation 100% on room air. A tender, swollen area
with increased warmth and firm consistency was noted to the anterior neck with normal overlying
skin, clinically resembling a nodule on the right thyroid gland. No signs of compression could be
elicited. There was no palpable lymphadenopathy, exophthalmos, pharyngeal erythema, irregular
heart rhythm, hepatosplenomegaly, peripheral or pretibial edema, tremors, or skin lesions. Other
general and systemic examinations were unremarkable.
Investigations
Thyroid function tests on admission revealed an undetectable (0.00 mU/L) level of thyroid
stimulating hormone (TSH) with elevated serum T3 and T4.
Computed tomography with contrast of the neck revealed a heterogeneous thyroid gland with
asymmetric enlargement of the right thyroid lobe and no lymphadenopathy. Ultrasonographic
imaging with color flow Doppler confirmed asymmetric enlargement of the right thyroid lobe with
two hypoechoic nodules in the inferior and superior poles with no internal vascularity measuring
9 cm and 3 mm in the greatest dimension, respectively (Figure 1). Reverse transcriptase real-time
qualitative polymerase chain reaction (RT-PCR) for SARS-CoV-2 from nasopharyngeal swabs
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was negative. Subsequent viral testing for respiratory syncytial virus, influenza A and B, coxsackie
A and B serology, and rapid strep A antigen was also negative. Levels of serum thyroglobulin and
thyroid peroxidase antibodies were undetectable. Levels of serum C-reactive protein (CRP) and
erythrocyte sedimentation rate (ESR) were 8.6 mg per dL (normal <3.0 mg/dL) and 49 mm per
hour (normal <29 mm/hr), respectively.

Figure 1. Ultrasound of the right thyroid lobe performed during the thyrotoxic phase showing areas
of hypoechogenicity.
Differential Diagnosis
From the history, physical examination and thyroid function tests; the possible causes of painful
thyroid with thyrotoxicosis were evaluated. A differential of Grave’s disease, toxic multinodular
goiter, toxic adenoma, follicular thyroid carcinoma, iodine toxicity, Hashimoto’s thyroiditis, and
DeQuervain’s subacute thyroiditis was considered. Thyroid peroxidase and thyroglobulin
antibodies were negative along with a lack of associated, systemic clinical findings effectively
eliminating Graves disease and autoimmune thyroiditis. The timing of symptoms and elevated
inflammatory markers make multinodular goiter, toxic adenoma, follicular carcinoma and iodine
toxicity less likely. The ultrasound findings and elevated ESR/CRP were strongly indicative of
subacute thyroiditis. The negative viral panel, lack of recent viral infection, and post-vaccination
symptomatology indicate a suspicion of DeQuervain’s subacute thyroiditis induced by the mRNA1273 SARS-CoV-2 vaccine.
Treatment
The patient was treated with analgesics, oral dexamethasone at 6 mg/day, and propranolol at
20mg/day. After one day of inpatient hospitalization, the patient clinically felt better with
improvement in her heart rate and neck pain. She was prescribed an oral methylprednisolone 4mg
taper for 6 days and propranolol upon discharge from the hospital.
Follow-Up
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The patient’s neck pain resolved with steroid medications. On 1 month follow up, her thyroid
function resolved back to normal (TSH 0.365 uIU/mL; T4 1.02 ng, dL; T3 2.96 pg/mL). She was
advised to periodically follow up for monitoring of her thyroid function.
Discussion
As of May 2021, an estimated 1.34 billion vaccines have been administered against the COVID19 infection. As more people get the vaccine, the side effect profile is becoming more understood.5
Rare complications from the vaccine are coming to light, as in the instance of our patient.6
Traditionally, painful subacute thyroiditis is frequently preceded by an upper respiratory tract
infection, therefore a viral cause is implicated. The typical course is a period of thyrotoxicosis
followed by hypothyroidism for several months. Thyroid function subsequently begins to
normalize in the majority of patients between 6 to 12 months after onset.1 However, our patient
resolved in the next four weeks. The incidence of subacute thyroiditis is observed to increase
during summer when viral outbreaks are higher, especially of coxsackievirus and echovirus.7,8 In
fact, a whole range of viruses including adenovirus, orthomyxovirus, EBV, CMV have been linked
to subacute thyroiditis.6
During the 2002 SARS outbreak, autopsy reports demonstrated thyroid injury. Cytotoxic effect in
subacute thyroiditis is postulated to be the result of cytologic T- cell recognition of follicular viral
antigens. The follicles that are infiltrated will often rupture due to an unstable basement
membrane.9
Data on the relationship between SARS-CoV-2 virus and the thyroid has been emerging and
rapidly increasing since March 2020. It is known that the thyroid gland and the virus are associated
in complex interplay. It is thought that the SARS-CoV-2 virus seems to be working on the ACE2
receptors as the main receptor to invade human cells.10 More research is showing that the
expression levels of ACE2 on the thyroid gland are more than in the lungs.4 It is suspected that
SARS-CoV2 has the capacity to infiltrate the thyroid and lead to subacute thyroiditis.
There are spike proteins on the surface of SARS-CoV-2 which bind to the ACE2 cell receptors.
As of now the exact makeup of the COVID mRNA vaccine is not available. However, the
vaccine that is made is programmed to encode for these spike proteins, inducing the humoral
production of antibodies against these conduits.11
It is theorized because these spike proteins have a strong affinity for the ACE2 receptor, the
subsequent antibody may also have an affinity. This would cause an antibody-mediated
inflammatory response to any tissue with the ACE2 receptor.12 Further, this can lead to
infiltration of the thyroid follicles causing activation of cytologic T-cell response to a virus-like
antigen at the thyroid follicle. 12
The CDC recommends reporting these rare side effects to the Vaccine Adverse Event Reporting
System. Anecdotal reports of subacute thyroiditis have been reported following the SARS-CoV2 mRNA vaccine, however no accounts have been published. Based on the presented case, we
believe subacute thyroiditis should be a consideration with all patients who present with similar
findings after receiving the vaccine.
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